Engitix is accelerating drug discovery for diseases including fibrosis and solid tumors. Many oncology drugs fail as they were identified by testing compounds on human cells grown on artificial substrates ignoring the impact of the extracellular matrix (ECM). The ECM is a dynamic bioactive acellular environment that influences solid tumor development. Engitix has developed a platform that deconvolutes the bioactive role of the tissue-specific and disease-specific acellular ECM to recreate physiologically realistic in vitro 3D platforms. Their platform can then be used to generate new, more relevant therapeutics against fibrosis and solid tumors, as well as find meaningful biomarkers to ensure delivery to the right patients.

Engitix

Founded: 2016
Location: London, UK
Employee range: 11 - 50
Funding: $54M Jan 2022

Short description:

Drug notes:

Long description:

Jobs: